|Day's range||3.5000 - 3.7000|
The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.
Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.
AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.
J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.
A total of 155 tests were conducted by two different third-party labs using four different testing methods on samples from the same bottle tested by the FDA's contracted lab, the company said. The tests are the latest effort by J&J to prove the safety of its widely used consumer product after the test by the FDA prompted J&J to undertake a nationwide recall of one lot of Johnson's Baby Powder in October.
The “Asbestos in Talc Symposium,” sponsored by the Food and Drug Administration, was dominated by industry hands: Most of the 21 non-government participants had done work for talc companies, such as testing and serving as expert witnesses and consultants, symposium documents and other records show. Key sessions were led by witnesses for Johnson & Johnson in lawsuits alleging the company failed to warn customers that its Baby Powder was tainted with cancer-causing asbestos, the records show. Over the past 50 years, the FDA has relied upon - and often deferred to - industry even as outside experts and consumers repeatedly raised serious health concerns about talc powders and cosmetics, a Reuters investigation found.
And according to data from Deutsche Bank Research, opioid-related deaths per million inhabitants has drastically increased in the U.S. compared to the other Organization for Economic Cooperation and Development (OECD) countries.
Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
AstraZeneca shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukaemia drug, in a challenge to rival AbbVie. AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go ahead for the company's Calquence drug to treat chronic lymphocytic leukemia (CLL), one of the most common types of leukaemia in adults. The drug was approved under a new speedy review programme in collaboration with drug watchdogs in Canada and Australia, and was also approved to treat small lymphocytic lymphoma, a similar disease.
Investing.com – President Donald Trump tweeted on Friday the federal government is working on a plan to let Florida and other states import lower-priced prescription drugs for residents.
FRANKFURT/PARIS, Nov 21 (Reuters) - Sanofi is considering a joint venture or outright sale among options for its consumer healthcare unit, sources told Reuters, as the French drugmaker prepares to present a new strategic plan next month. An initial public offering (IPO) of the unit, which could be worth around $30 billion according to two sources familiar with the matter, is also on the cards. Sources cautioned that no final decision had been made.
More than 1,350 Australian women won a seven-year-old class action lawsuit on Thursday against Johnson & Johnson (J&J) for misleading patients and surgeons about the risks of the pharmaceutical giant's pelvic mesh implants. The suit is one of many J&J has faced in the United States, Canada and Europe over the implants, used to treat urinary incontinence and pelvic organ prolapse, in which organs shift from normal positions. J&J in October agreed to pay nearly $117 million to resolve claims in 41 U.S. states and the District of Columbia.
Myovant's (MYOV) phase III study evaluating lead pipeline candidate, relugolix, in patients with advanced prostate cancer meets primary endpoint.